Sign inJoin free

Watch / CEOs & MDs

LTR Pharma's ASX debut

12 Dec 20235:15

LTR Pharma's ASX debut

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Dr Julian Chick, non-executive chairman of LTR Pharma (LTP), reveals that the company, which recently debuted on the ASX and raised approximately $7 million through a 20 cent share IPO, is developing a nasal version of an erectile dysfunction (ED) drug, with brands like Viagra forming an integral part of their model. The nasal ED drug is expected to provide rapid onset, improving spontaneity in relationships. While traditional oral ED drugs require an extended waiting period post-consumption, Julian states that this nasal spray will be active within a mere 5 to 10 minutes.

Julian shares that clinical studies have been conducted to demonstrate the effect of the nasal spray and underscores the market's demand for such a product. As the prolonged use of oral ED drugs often leads to their discontinuation due to ineffectiveness, LTR Pharma's nasal ED drug could prove to be an effective substitute. The objective now, Julian explains, is to raise capital through the IPO for an upcoming study, following which they intend to seek approval from the FDA before embarking on a global launch programme.

Looking ahead, Julian notes that the clinical study will be conducted the following year, and all gathered data is expected to be submitted to the FDA by the end of 2024 or the beginning of 2025. No side effects have been noted so far owing to the product's lower dosage, which is delivered more directly and thus mitigates the potential for side effects. Furthermore, Alpine Capital is mentioned as an entity that worked positively with LTR Pharma.

Below is an unedited transcript of the interview:

Let's get back to the medtech space now, because we have actually seen the debut of a new company on the ASX 200 on the on the ASX, I should say LTR Pharma and Doctor Julian Chick, the non-executive chairman of LTR Pharma here with us. So congratulations on your debut. What are you seeing?

0:19

Yeah, well. Thank you. Thanks for having us. Yeah. Look, I think it's been a good start, uh, for the company. Uh, worked well with Alpine Capital and now allows us to move forward, uh, with the rest of the development pipeline and move into, you know, commercializing our product. So, yeah, it's been a good debut, I think, particularly given the market conditions. We're just hoping to get your share price coming up on the screen as well. You raised around $7 million through the IPO price with 20 cent shares. So what sort of demand did you see for that?

0:52

Yeah. Very strong. Uh, I think that was based around the simplicity of the story. Uh, the story is, um, you know, it's an easily understood story. We are developing a, a nasal version of an erectile dysfunction drug or ed drugs. Uh, best known for the brands like Viagra. Uh, but this is a rapid onset, and that's a major part of the market is being able to give spontaneity back into relationships as opposed to taking oral and waiting long periods of time. And so as a result of that, people understood the story. They saw that the path forward for us, uh, and why we're doing the raise. So raising $7 million, I think we are three and a half times at least oversubscribed. So very strong demand. And that's probably reflected on how the shares of performance performed today. This morning, uh, when we listed, uh, up from the 20 cent float, as you mentioned. Yeah. They're now at 40. So congratulations. You've doubled in just a couple of hours on the market. You mentioned that that new drug. Just tell us the

1:52

importance of this. And I guess helping to take the stigma away as well from Eddie.

1:59

Yeah, you're absolutely right. It's, um, it's one of those things that men are very poor at talking about all their conditions and and health. Uh, but actually erectile dysfunction is a real issue for, for many, many men. Uh, and also moreover, um, it's also an issue in terms of, uh, how they're administered. So, you know, we saw the rise of the Viagra of this world come onto the market as oral drugs. But as we know, if we take something, uh, we swallow a pill, it takes some time to have an effect. The benefit of what we're doing here is our nasal sprays. We. It's administered up the nose. We've done clinical studies to show that this is the case. And it's active within 5 to 10 minutes. And so the key there is that you can keep that spontaneous component. And the data shows us that at least half of the cases. And moreover the longer people use oral Ed drugs, the more likely they are to stop using them because they find them ineffective. So, you know, we see that there's a really great clear market position for us. Um, you know, we know the

2:59

product works. We have one small study to do, and that's the reason for raising the capital through the IPO. Uh, and then we'll look at submitting to the FDA for approval and then going into a global launch program. So we're right on the cusp of the business. So when do you expect completion? Is this not till 2025? Correct? Yes. Can you just give us a bit of a time frame? Yeah, yeah. So next year we'll run the clinical study and then we will combine all the data and we will submit that into the FDA towards the end of 2024 into 2025. Um, and, and then look through that process at the FDA in terms of review. But that shouldn't be a long process. As we know the data package, we have all the data package. We've met with the FDA. We have all of those guidelines. But I would also say that one of the benefits we do have is that there is an enormous demand for this, and it's seen as a genuine issue as well as as physicians, seeing that there's a need for this. Um, it helps with,

3:59

you know, um, mental states confidence, you know, all of these things that where people suffer this, uh, issue significantly, that it plays an emotional toll on relationships, etc.. So we believe that there may be ability for us to get into some market positions such as early access early, and let's see that come through in 2024. So should be solid news flow coming through in 2024 right through into 2025. When we look at the actual dosage, so you're saying a lower dose, but it is going to be, uh, faster effect and delivery. What kind of side effects have you seen in trials?

4:41

Yeah. So none. So that's one of the benefits of the lower dose. So we all have heard the stories of the Viagra. And be careful of your heart and your heart condition and all of those sort of things, um, and conditions inside issues. But what we're doing here is we're giving a nasal spray up the nose, allows us to give that quicker onset, as you say, because it's absorbed through the nasal mucosal layer. But also it means that because it's a more direct route to administration, we can lower the dose, which then puts lower protection for side effects of which we have not seen in.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy